MYUNGMOON Pharm co.,Ltd (017180.KS)
KRW 1860.0
(-0.59%)
KRW 1860.0
(-0.59%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.52 Billion KRW | -157.51% |
| 2022 | 7.86 Billion KRW | 215.63% |
| 2021 | -6.8 Billion KRW | 75.48% |
| 2020 | -27.75 Billion KRW | -33.22% |
| 2019 | -20.83 Billion KRW | -2208.01% |
| 2018 | 988.26 Million KRW | -87.34% |
| 2017 | 7.8 Billion KRW | 15.74% |
| 2016 | 6.74 Billion KRW | 141.81% |
| 2015 | -16.13 Billion KRW | -2218.93% |
| 2014 | 761.49 Million KRW | -25.78% |
| 2013 | 1.02 Billion KRW | 108.36% |
| 2012 | -12.27 Billion KRW | -369.51% |
| 2011 | 4.55 Billion KRW | 48.44% |
| 2010 | 3.06 Billion KRW | 4.31% |
| 2009 | 2.94 Billion KRW | -39.53% |
| 2008 | 4.86 Billion KRW | -26.13% |
| 2007 | 6.58 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.21 Billion KRW | 69.89% |
| 2024 Q2 | -1.53 Billion KRW | -26.39% |
| 2023 Q4 | -4.03 Billion KRW | -329.41% |
| 2023 FY | -4.52 Billion KRW | -157.51% |
| 2023 Q3 | -938.89 Million KRW | -585.61% |
| 2023 Q2 | -136.94 Million KRW | -136.01% |
| 2023 Q1 | 380.31 Million KRW | -91.79% |
| 2022 Q2 | 2.17 Billion KRW | 125.43% |
| 2022 FY | 7.86 Billion KRW | 215.63% |
| 2022 Q1 | 965.28 Million KRW | 112.06% |
| 2022 Q4 | 4.63 Billion KRW | 4832.22% |
| 2022 Q3 | 93.92 Million KRW | -95.68% |
| 2021 Q1 | 617.96 Million KRW | 107.75% |
| 2021 Q2 | 656.58 Million KRW | 6.25% |
| 2021 Q4 | -8 Billion KRW | -5882.07% |
| 2021 Q3 | -133.82 Million KRW | -120.38% |
| 2021 FY | -6.8 Billion KRW | 75.48% |
| 2020 FY | -27.75 Billion KRW | -33.22% |
| 2020 Q3 | -4.8 Billion KRW | 49.91% |
| 2020 Q4 | -7.97 Billion KRW | -65.89% |
| 2020 Q2 | -9.59 Billion KRW | -82.05% |
| 2020 Q1 | -5.26 Billion KRW | 57.41% |
| 2019 Q4 | -12.37 Billion KRW | -772.72% |
| 2019 FY | -20.83 Billion KRW | -2208.01% |
| 2019 Q3 | -1.41 Billion KRW | 73.03% |
| 2019 Q2 | -5.25 Billion KRW | -290.59% |
| 2019 Q1 | -1.34 Billion KRW | -423.66% |
| 2018 Q3 | -492.72 Million KRW | -203.03% |
| 2018 FY | 988.26 Million KRW | -87.34% |
| 2018 Q1 | 586.86 Million KRW | -41.14% |
| 2018 Q2 | 478.22 Million KRW | -18.51% |
| 2018 Q4 | 415.91 Million KRW | 184.41% |
| 2017 FY | 7.8 Billion KRW | 15.74% |
| 2017 Q2 | 5.73 Billion KRW | 693.59% |
| 2017 Q3 | 351.88 Million KRW | -93.87% |
| 2017 Q1 | 722.77 Million KRW | -17.67% |
| 2017 Q4 | 996.96 Million KRW | 183.33% |
| 2016 Q1 | 2.26 Billion KRW | 115.1% |
| 2016 Q4 | 877.91 Million KRW | -22.64% |
| 2016 Q3 | 1.13 Billion KRW | -54.06% |
| 2016 Q2 | 2.47 Billion KRW | 9.2% |
| 2016 FY | 6.74 Billion KRW | 141.81% |
| 2015 Q3 | 1.16 Billion KRW | 164.83% |
| 2015 Q1 | -514.06 Million KRW | -287.05% |
| 2015 Q4 | -14.98 Billion KRW | -1382.2% |
| 2015 Q2 | -1.8 Billion KRW | -250.74% |
| 2015 FY | -16.13 Billion KRW | -2218.93% |
| 2014 Q3 | -105.14 Million KRW | -119.28% |
| 2014 Q2 | 545.41 Million KRW | 1075.57% |
| 2014 Q4 | 274.82 Million KRW | 361.37% |
| 2014 Q1 | 46.39 Million KRW | 133.02% |
| 2014 FY | 761.49 Million KRW | -25.78% |
| 2013 Q3 | -418.5 Million KRW | -143.81% |
| 2013 FY | 1.02 Billion KRW | 108.36% |
| 2013 Q2 | 955.18 Million KRW | 51.67% |
| 2013 Q4 | -140.48 Million KRW | 66.43% |
| 2013 Q1 | 629.78 Million KRW | 131.49% |
| 2012 Q1 | 896.54 Million KRW | 0.0% |
| 2012 FY | -12.27 Billion KRW | -369.51% |
| 2012 Q2 | -8.63 Billion KRW | -1062.71% |
| 2012 Q3 | -2.17 Billion KRW | 74.85% |
| 2012 Q4 | -2 Billion KRW | 7.85% |
| 2011 Q1 | 3 Billion KRW | 0.0% |
| 2011 Q3 | 1.33 Billion KRW | -35.77% |
| 2011 FY | 4.55 Billion KRW | 48.44% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 2.08 Billion KRW | -30.63% |
| 2010 Q1 | 703.3 Million KRW | 0.0% |
| 2010 Q3 | 1.23 Billion KRW | -50.04% |
| 2010 FY | 3.06 Billion KRW | 4.31% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 2.47 Billion KRW | 251.51% |
| 2009 Q3 | 1.05 Billion KRW | 6.16% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 2.94 Billion KRW | -39.53% |
| 2009 Q1 | 1.31 Billion KRW | -26.76% |
| 2009 Q2 | 994.85 Million KRW | -24.23% |
| 2008 Q3 | -1.18 Billion KRW | -154.3% |
| 2008 Q4 | 1.79 Billion KRW | 251.11% |
| 2008 Q2 | 2.18 Billion KRW | 0.0% |
| 2008 FY | 4.86 Billion KRW | -26.13% |
| 2007 FY | 6.58 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 36.988% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 107.803% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 92.406% |
| HANDOK Inc. | -28.79 Billion KRW | 84.287% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 46.23% |
| Yuhan Corporation | 93.5 Billion KRW | 104.839% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 140.682% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 81.764% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 103.094% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 228.964% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -80.53% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -118.179% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 120.261% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 36.988% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 78.392% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 226.273% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 96.174% |
| JW Holdings Corporation | 19.02 Billion KRW | 123.782% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 94.267% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 102.129% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 112.227% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 92.107% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 173.914% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 372.001% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 190.411% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 36.988% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 112.241% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 104.058% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 112.227% |
| Yuhan Corporation | 93.5 Billion KRW | 104.839% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 72.154% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -16.754% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 173.945% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 112.227% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 123.934% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 109.376% |
| CKD Bio Corp. | -24.19 Billion KRW | 81.297% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 118.919% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 116.491% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 115.197% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 92.107% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 109.626% |
| Boryung Corporation | 40.2 Billion KRW | 111.255% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 85.557% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -80.53% |
| JW Lifescience Corporation | 28.14 Billion KRW | 116.077% |